PD-1 Blockade-activated Neoantigen Specific Cellular Therapy For Advanced Relapsed Non Small Cell Lung Cancer

doi:10.21203/rs.3.rs-5024390/v1

Background

Due to its strong immunogenicity and tumor specificity, neoplastic antigen has emerged as an immunotherapy target with wide therapeutic prospect and clinical application value. Anti-programmed death-1 (PD-1) antibodies reinvigorate T cell-mediated antitumor immunity .So we conducted single-arm trial to assess the safety and efficacy of PD-1 blockade(Camrelizumab)-activated Neoantigen Specific Cellular Therapy (aNASCT) on advanced relapsed non-small lung cancer( NSCLC)(ClinicalTrials.gov NCT03205930).

Methods

Neoantigenic peptides were designed and manufactured according to the whole-exome sequencing and RNA sequencing of fresh biopsy tissues and peripheral blood as well as bioinformatics analysis.All participants received subcutaneous injection of mature DCS (mDCS) loaded with neoantigens on day 8 and subcutaneous injection of mDC-induced autologous somatic toxic T lymphocytes (CTLS) on day 27 for a period defined as 28 days (4 weeks). Enrolled patients received at least 3 cycles of therapy.The safety and efficacy of the treatment were evaluated by evaluating adverse reactions, progression-free survival (PFS), overall survival (OS).

Results

A total of 13 patients with advanced replased NSCLC were enrolled in this study. All 13 patients received at least 3 cycles of aNASCT treatment, of which 2 patients received at most 12 cycles of treatment. Treatment-related adverse events (AEs) occurred in 4/13 (30.8%)patients with transient fever below 38℃.The objective response rate (ORR) across the 13 enrolled patients was 7 of 13 (53.85%).The disease control rate (DCR) was 8 of 13 (61.54%). The median PFS was 11 months (95% CI 6.1–15.9), and the median OS was 15 months(95% CI 11.5–18.5).

Conclusions

Our findings indicate that aMASCT therapy was safety and immunogenicity of patients with advanced relapsed NSCLC, suggesting its promising potential in cancer immunotherapy.

Neoantigen

Cell therapy

Immunotherapy

Advanced Non Small Cell Lung Cancer

Cancer immunotherapy, encompassing cell-based cancer immunotherapies and immune checkpoint inhibitors(ICIs) ,has revolutionized the treatment paradigm^[1–2]. Cell-based cancer immunotherapies, including activation and amplification of the patient’s autologous T lymphocytes in vitro and then returning them to the body to kill tumor cells ^[3], have demonstrated remarkable efficacy in advanced cancers^[4–5]. Multiple antigen-stimulating cell therapy (MASCT) is the first therapeutic intervention combining DCs vaccines and ACT in a single treatment modality to elicit both active and passive immune response^[6] .Our previous study has demonstrated that due to the weak immunogenicity of antigen, MASCT treatment for patients with non-small cell lung cancer (NSCLC) who were intolerant to standard therapies was still unsatisfactory^[7]. Consequently, effective and low toxicity therapies for advanced NSCLC are urgently needed.

Tumor neoantigens, which are mutated peptides that bind with the major histocompatibility complex (MHC) on the surface of malignant cells, have the potential to be recognized by T cells and elicit robust and specific antitumor immune responses.A growing body of evidence indicates that immunotherapy targeting neoantigens has significant anti-tumor effects on various cancers ^[8–9] .In support of these findings, specific cell therapy targeting neoantigens may strengthen patients´ endogenous immune response against cancer^[10].Meanwhile, NSCLC is recognized as one of the most ICI-sensitive cancers. ICI can restore suppressed immune responses to tumors by inhibiting ligand-receptor interactions involving lymphocyte regulatory molecules^[11]. Mutation-derived neoantigens may be critical tumor-specific targets for ICI-reactivated CTLs^[12].We reasoned that this strategy could augment the response rates and durability of responses over the results of PD-1 inhibition alone by inducing, expanding, and broadening the tumor-directed T cell repertoire. Therefore, we analyzed the data from our phase I/IIa trial to assess the safety and efficacy of PD-1(Camrelizumab) blocked neoantigen specific cellular therapy(aNASCT) in advanced NSCLC after standard treatment.

Study design and patients

Between June 2017 to June 2020,Patients aged between 18 and 75 years were provided informed consent and enrolled to a prospective,single center, single-arm,pilot clinical trial (NCT03205930) approved by the Ethics Committee of Lianyungang Clinical College of Nanjing Medical University (2017008). The study was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent.

Eligible patients were clinically or radiographically evident, pathologically confirmed stage IV or recurrent metastatic NSCLC, including squamous cell carcinoma and adenocarcinoma, who failed multiple lines of therapy(at least two systemic therapies).Other inclusion criteria included a life expectancy of over 3 months,an Eastern Cooperative Oncology Group (ECOG) score of 0–2,adequate hematologic and organ functions,tumor lesions could be evaluated by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST) ,cessation of any cancer therapy for at least 1 month before enrollment.Key exclusion criteria were previous treatment with anti-CTLA-4 or anti-PD-1/PD-L1 therapy, active autoimmune disease.The patients enrolled were undergoing tumor biopsies and blood withdrawing, including formalin-fixed paraffin-embedded (FFPE) samples, biopsy specimen, serum samples and serous effusions.

Study treatment

All participants were treated with a subcutaneous injection of 1–10×10⁷ mature DCs (mDCs) loaded with neoantigens and multiple antigens on Day 8 and autologous cytotoxic T lymphocytes (CTL) induced by mDCs on Day 27 (1–10 × 10⁹ per infusion cycle). A treatment cycle was defined as 28 days (4 weeks). The enrolled patients received at least 3 cycles,up to 12 cycles. Patients with disease progression (PD) ,death or unmanageable toxic effects were taken off of the study(Fig. 1).

Study endpoints and assessments

The primary endpoints of this study included safety and feasibility. The secondary endpoints included progression-free survival (PFS,)overall survival (OS), objective response rate (ORR), and disease control rate (DCR).

The tumor assessment of each patient, including contrast-enhanced computed tomography and magnetic resonance imaging (MRI) of the brain,was conducted before the first treatment. Tumor responses were assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria after 3 cycles and subsequently every 12 weeks based on investigator assessment. Toxicity assessments, adverse events, laboratory values, ECG, and vital signs were assessed regularly and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (v.4.03) for 36 months after the final cycle or until the patient was lost to follow-up.

Whole Exome Sequencing

FFPE tumor samples and matched autologous peripheral blood mononuclear cells (PBMCs) samples of each patient were sent to the facility of Geneseeq Technology Inc (Nanjing, China) for subsequently whole exome sequencing( WES) analysis^[13–14].

Bioinformatics and mutation calling

All raw data output from sequencing were filtered out adapter and trimming low quality reads with Illumina illustration. Clean reads were aligned to the reference genome hg19 using BWA. Duplicate site were makered using Picard. The paired tumor and normal data were used to detected single nucleotide variations (SNV) and small insertions/deletions (Indel) using Mutect2. All detected variation were annotated by Annovar and filtered with frequence more than 5% and over than 20 supported reads for further analysis.

Human leukocyte antigen (HLA) typing

HLA class I major loci A,B,C were typed at four-digit resolution by Polysolver^[15]using normal sample’s WES sequence data.

Neoantigenic peptides(neo-peptides) prediction and prioritization

All mutation were annotated by Annovar. NeoORF were annotated manually and translated into amino acid sequence. The 31 long peptides which containing mutation in middle site and extend 15 amino acids of both sides were selected for epitopes prediction. All possible 8-11mers peptides sequences were computed affinity and stability cooperated with the patient’s HLA-I subtypes using netMHC4.0/netMHCpan3.0 and netMHCstab/netMHCpan 2.0.

Epitopes with stability more than 2 hours were defined as positive presented epitopes. Neo-peptide which contained 31 amino acids were classified as four levels: Neo-peptides with more than two positive epitopes were defined as level 4.Otherwise, neo-peptides containing only single epitope with affinity value lower than 150nM were defined as level 3, and neo-peptides containing single epitope affinity value which ranged from 150nM to 500nM were defined as level 2, and affinity value higher than 500nM were defined as level1. All neo-peptides were ranked by high levels and within same level ranked by the mutation frequence. For each patient, the top 1–15 neo-peptides were selected for further peptides synthesis and using in further aNASCT cell culture.

Generation and assessment of aNASCT

MASCT is the first therapeutic intervention combining DCs vaccines and ACT in a single treatment modality to elicit both active and passive immune response, MASCT was prepared as our published study^[7]. Peripheral blood mononuclear cells (PBMCs) from patients were obtained by density gradient centrifugation using Lymphoprep (Nycome-dPharma, Oslo, Norway) and incubated 1.5 h at 37°C in a saturated 5% CO² incubator. After that, adherent monocytes were cultured with GM-CSF (1000 U/mL) and IL-4 (500 U/mL) in AIM-V (Gibco, Carlsbad, CA) to differentiate into immature DCs (imDCs). The imDCs were pulsed by a peptide pool of neo-antigens and basic antigens (1 µg/mL/peptide) and then cultured with a maturing cocktail (IL-6, 1000 U/mL; TNF-α, 1000 U/mL; IL-1β, 10,000 U/mL; PEG2, 1 µg/mL; Poly I:C, 10 µg/mL) to differentiate into antigen-presenting mDCs. In order to prepare for the activated CTL infusion, frozen non-adherent PBMCs were co-cultured with antigen-loaded mDCs in the presence of IL-2 (1000 U/mL; R&D Systems Inc, Minneapolis, MN) about 4 weeks .The anti-CD3 antibody (50 ng/mL; eBioscience, Inc., San Diego, CA) was added 3 days after co-culturing. The autologous T cells of Neo-ASCT were then incubated with 1.5 mg SHR-1210 (a fully human IgG4 monoclonal antibody against PD-1) ^[16]ex vivo for 40 min in a 37°C thermostat, referred to as aNASCT, and finally transferred to patients.

Flow cytometry analysis

The circulating tregs from patients were assessed using flow cytometry as previously described^[7]. Antibodies for surface markers and intracellular protein staining were obtained from BD Biosciences including anti-CD80, -CD83, -CD86, -CD3, -CD4, -CD8, -CD25, -CD127, -PD-1, -IL-2,IL-4,IL-6,IL-10,TNF- α,-IFNγ. All the flow cytometry assays were determined using a FACSCalibur Flow Cytometer (BD Pharmingen), and the data were analyzed by the FlowJo software (Tree Star Inc.).

IFN-γ Enzyme-Linked Immunospot Assay (ELISPOT)

IFN-γ ELISPOT kit (U-CyTech Biosciences, Netherlands) was used to detect the levels of peptide reactivity in the CTL. The ELISPOT assay was conducted and analyzed according to standard protocol. About 2×10⁵ cells were incubated with the neoantigen peptides pool,positive peptides or irrelevant peptides using a 48-well ELISPOT plate overnight at 37°C in a saturated 5% CO². The resulting spots were scanned by Elispot CTL Reader (Cell Technology Inc, Columbia, MD) and analyzed with Elispot software (AID, Strassberg, Germany).

Statistical Analysis

Patient characteristics, clinical outcomes were presented using simple descriptive statistics. GraphPad Prism 9.0 software was used to plot survival curves and perform data analyses. Data samples were compared using a 2-tailed t-test.The Kaplan-Meier curves was used to estimated PFS and OS with corresponding 95% CIs. P < 0.05 was considered significant in all the analyses.

Patient characteristics and neoantigen identification

We conducted a single-arm, pilot study to test the efficacy of aNASCT in patients with relapsed advanced lung cancer(ClinicalTrials.gov NCT03205930). The aNASCT formulation and the overall schedule of administration are shown in Fig. 1.From June 2017 to June 2020, Lianyungang Clinical College of Nanjing Medical University recruited 21 patients with advanced non small cell lung cancer who had relapsed under standard multiline treatment. Except for 3 patients who had failed biopsies, tumor and blood samples were collected for high-throughput sequencing from 18 of 21 patients. After performing WES on the DNA from both tumor and blood samples,5 patients were excluded due to death from rapid tumor progression. The participant flow through this study is outlined in Fig. 2. The demographics and baseline clinical characteristics of the included 13 patients are listed in Table 1.

Table 1

Baseline clinical characteristics of patients
Patient ID.	Sex	Age	Pathology	ECOG PS	Driver genes	Lines of prior therapy	Treatment cycle
P01	M	67	A	0	WT	2	10
P02	F	64	S	0	EGFR exon19Del	3	4
P03	M	73	S	1	WT	2	6
P04	F	41	S	1	WT	4	9
P06	F	56	A	0	WT	2	12
P08	M	63	A	1	EGFR exon19Del、TP53	3	3
P09	M	44	A	0	WT	3	12
P11	M	61	A	1	WT	4	4
P13	M	39	A	0	WT	3	9
P14	M	58	S	1	WT	3	9
P16	F	63	S	1	WT	3	7
P17	M	60	A	1	EGFR L858R	2	6
P21	M	67	A	2	WT	4	3
M male, F female, A adenocarcinoma, S squamous cell carcinoma, ECOG PS Eastern Cooperative Oncology Group performance status, WT wild-type, EGFR epidermal growth factor receptor

To produce the personalized neoantigen peptide, patients firstly underwent 416 gene panel sequencing and human leukocyte antigen (HLA)-I typing as outlined in Table 2. After stepwise filtering criteria, the top 3–15 neopeptides according to the prediction algorithm were selected for each patient (Table 2). The turn-around time of the whole process was mostly between 4 months.

Feasibility of aNASCT manufacturing

In total, 13 patients underwent aNASCT treatment. PBMCs were collected by leukapheresis for aNASCT following peptide synthesis. Each patient received no less than 3 cycles of treatment. The immunophenotypes and characteristics of mDCs or CTL should be evaluated before treatment. Almost all mDCs expressed mature molecular markers (CD80⁺, CD83⁺, CD86⁺, HLA-DR⁺) while imDCs did not expresse these markers (Fig. 3a). In addition, a considerable percentage of CTLs expressed granzyme B and IFN-γ compared with PBMC(Fig. 3b), which indicated that mDCs and CTLs were activated before infusion. These data establish the feasibility of this advanced manufacturing platform and support further study.

Safety of aNASCT

aNASCT treatments were well tolerated.The most common observed immune-related adverse events (AEs) was transient fever (4/13, 30.8%),but almost all fevers were mild and below 38°C ,and resolved within 12h spontaneously. Other immune-related AEs were not observed. (Table 3).

Table 2 Patient HLA，number of neoepitopes

Patient ID	HLA I binders	Nonsynonymous mutations HLA I binders	Number of expressed neoepitopes	Neo-peptides in aNASCT
P01	HLA-A11:01:01/HLA-A01:06:01 HLA-B14:01:01/HLA-B15:02:01 HLA-C08:02:01/HLA-C08:01:01	25	8	8
P02	HLA-A11:02:01/HLA-A24:02:01 HLA-B39:01:01/HLA-B51:01:01 HLA-C14:02:01/HLA-C07:02:01	27	11	11
P03	HLA-A11:01:01/HLA-A02:06:01 HLA-B13:01:01/HLA-B46:01:01 HLA-C03:04:01/HLA-C01:03:01	53	35	10
P04	HLA-A11:02:01/HLA-A11:02:01 HLA-B52:01:01/HLA-B13:01:01 HLA-C12:02:01/HLA-C03:04:01	17	9	9
P06	HLA-A24:02:01/HLA-A02:03:01 HLA-B39:01:01/HLA-B48:01:01 HLA-C07:02:01/HLA-C08:01:01	14	6	6
P08	HLA-A03:01:01/HLA-A03:01:01 HLA-B57:01:01/HLA-B15:17:01 HLA-C06:02:03/ HLA-C07:01:02	77	26	10
P09	HLA-A24:02:01/HLA-A11:01:01 HLA-B48:01:01/HLA-B48:01:01 HLA-C08:01:01/HLA-C07:02:01	26	8	8
P11	HLA-A30:01:01/HLA-A33:03:01 HLA-B44:03:01/HLA-B13:02:01 HLA-C06:02:01/HLA-C14:03:01	22	14	14
P13	HLA-A30:01:01/HLA-A30:01:01 HLA-B40:01:01/HLA-B15:01:20 HLA-C04:03:01/HLA-C03:03:01	18	8	8
P14	HLA-A24:02:01/HLA-A02:01:01 HLA-B35:01:01/HLA-B15:01:01 HLA-C03:01:01/HLA-C07:02:01	53	15	15
P16	HLA-A24:02:01/HLA-A24:02:01 HLA-B40:01:02/HLA-B54:01:01 HLA-C01:02:01/HLA-C03:04:01	3	3	3
P17	HLA-A11:02:01/HLA-A11:01:01 HLA-B13:01:01/HLA-B35:01:01 HLA-C03:03:01/HLA-C03:04:01	18	10	10
P21	HLA-A03:01:01/HLA-A01:01:01 HLA-B57:01:01/HLA-B15:17:01 HLA-C06:02:03/HLA-C07:01:02	301	158	10

Table 3

Treatment-related AEs in all treated patients
AEs	All treated patients(n = 13)
	Grade 1–2 Grade 3–4
Fever	4	0
Flu-like symptoms	0	0
Chills	0	0
Dizziness	0	0
Fatigue	0	0

Efficiency of aNASCT

All 13 patients received at least 3 cycles of aNASCT treatment, of which 2 patients received at most 12 cycles of treatment, and 2 patients received only 9 cycles of treatment due to the COVID-19(Table 1).The tumor response of the remaining 13 patients is shown in Fig. 4. Patients with CR, PR, SD, and PD were 1,6,1,5.The objective response rate (ORR) was 7 of 13 (53.85%), while the disease control rate(DCR) was 8 of 13 (61.54%). As of June 30, 2024, the median PFS was 11 months (95% CI 6.1–15.9), and the median OS was 15 months(95% CI 11.5–18.5) (Fig. 4b-c). The median PFS was 15.5 months in the effective treatment group(CR + PR + SD), and 8 months in the ineffective treatment group༈PD༉(P = 0.0044). The median OS was 34 months in the effective treatment group, and 13 months in the ineffective treatment group(P = 0.0039) (Fig. 4d-e).

IFN-γ ELISPOT of aNASCT

To detect neoantigen peptide specific immune responses, IFN-γ ELISPOT was detected in vitro by autologous PBMC before aNASCT treatment and after each 3 cycles of treatment, respectively(Fig. 5).As shown in Fig. 5,after a period of treatment with aNASCT, most of the predicted synthesized new antigen peptides had obvious response, and the response rate increased with the increase of treatment period. However,There was no significant difference in the number of positive spots in patients who did not respond to treatment compared with those before treatment. The results indicated that aNASCT therapy did not induce a significant specific immune response in patients who did not respond to treatment.

Predictors associated with clinical outcomes.

Since not all patients responded to the treatment in this study, stratified analysis was performed. The number of treatment cycles undergone had significant effects on the patients’ survival prognoses(Fig. 6a-b). Both PFS and OS were significantly prolonged in patients receiving treatment ≥ 6 cycles,especially ≥ 9 cycles(P < 0.05).

Analysis of the circulating T cells

In order to understand the activation of CD4⁺CD25⁻ T cells and CD4⁺CD25⁺CD127⁻ Treg cells in the tumor microenvironment during treatment, we used flow cytometry to detect the cells in PBMC of patients before and after treatment, and the results are shown in Fig. 7. Before treatment with aNASCT, there was no significant difference in CD4⁺ CD25⁻T cells and Tregs in PBMC between the effective and ineffective groups (P > 0.05).After 3 cycles of aNASCT treatment, the percentage of CD4⁺ CD25⁻T cells increased (P < 0.05) in all groups.Tregs in the effective treatment group was significantly decreased than pre-treatment(P = 0.029), while Tregs in the ineffective treatment group was not significantly decreased(P = 0.7587).These results revealed the important role of Tregs in tumor microenvironment in the treatment of advanced NSCLC by aNASCT.

This study included patients with stage IV NSCLC who had failed standard treatment and were diagnosed with metastases or local recurrences by imaging. Such patients have higher tumor mutational burden and poor prognosis. Our previous single-center prospective study showed that the PFS of pretreated advanced NSCLC patients ,who were treated with aMASCT, was 4.5 months, and the OS was only 8.2 months ^[7]. The limited efficacy of MASCT may be related to the weak immunogenicity of tumor cells : most tumor cells only express low levels of tumor-specific antigens (TSAs) or tumor-associated antigens (TAAs), and their immunogenicity is so weak that the tumor cells are not sufficient to stimulate the body to produce a strong enough immune response. On the other hand, it may be related to the antigenic modulation of tumor cells: the immune response of the host to tumor antigens may lead to the reduction or loss of antigens on the surface of tumor cells, thus evading immune attack. Therefore, the selection of appropriate antigenic targets is a critical barrier for the success of cancer immunotherapy. Neoantigens are tumor-specific and expressed in tumor cells only,thus neoantigens can bypass the host central or peripheral immune tolerance to elicit or augment neoantigen-specific antitumor immunity with strong neoantigen binding.NSCLC bears a high mutational load ^[17]. Direct targeting of neoantigens with personalized NSCLC ,which bears a high mutational load ,provides an alternative approach to enhance tumor immunotherapy.

In this study, we show that aNASCT is safe and tolerable and can be conveniently administered for patients with advanced relapsed NSCLC. All of the adverse events were low-grade and transient. Among the 13 patients, four patients experienced transient fever below 38°C (30.77%, 4/13) for less than 12 hours, while other patients did not show immune-related treatment responses. Previously, our research team reported the incidence of aMASCT treatment-related adverse events was 56.3%. The results showed that aNASCT demonstrated good safety in the treatment of advanced NSCLC.

Although only one of the enrolled patients achieve CR, this study demonstrated a 53.85% ORR and 61.54% DCR in patients with recurrent advanced NSCLC who were treated with aNASCT. As of June 30, 2024, the median PFS was 11 months (95% CI 6.1–15.9), and the median OS was 15 months (95% CI 11.5–18.5).

Our previous study showed that the median PFS was 4.5 months and OS was 8.2 months in relapsed NSCLC patients receiving aMASCT ^[7]. The results indicated that patients benefited from the activation of the immune system by aNASCT, resulting in improved PFS and OS. Compared with similar research results, the aNASCT treatment for advanced NSCLC in this study has shown good efficacy, but due to the small sample size, more reliable experimental data require further research with an expanded sample size.

A previous study found that patients with hepatocellular carcinoma who received multiple courses(≥ 5) of MASCT after curative treatment might benefit more from cell-based immunotherapy^[18]. In this study, we presented the result that three or more cycles of aNASCT treatment was significantly associated with improved PFS and OS in both patients. Similarly, Jiang et al^[19] showed that two or more rounds of immunotherapy significantly improved DCR and OS among patients with advanced pancreatic cancer. Based on these data, a cumulative effects of immunotherapy is effective in prolonging the patient survival.

Furthermore, we have measured the percentage of neoantigens that can stimulate the response of CD4 + CD25- T cells and CD4 + CD25 + CD127- Treg cells.As shown in, after three cycles of aNASCT treatment, there was no significant change in the ineffective group, which may be the reason of poor immune response to aNASCT treatment.Treg cells are generally considered to be cells with immunosuppressive functions^[20–21]. Based on the above results, ineffective anti-tumor immune responses in part of patients with advanced NSCLC contributed to tumor progression and poor outcomes,which may be related to the tumor-suppressive microenvironment caused by immune imbalance.

Overall, our findings have demonstrated that aNASCT is feasible, safe, and capable of inducing specific T-cell immunity and therapeutic benefits. However, the development of aNASCT still faces many challenges, such as the reasons for effective and ineffective treatment, and whether there are corresponding markers that can be easily detected to pre-evaluate the therapeutic effect. Next, we are planning to conduct basic and clinical trials in order to improve the therapeutic effect of tumor neoantigen therapy. Finally, we believe that tumor neoantigens are currently considered a promising field in cancer immunotherapy.

aNASCT PD-1 blockade(Camrelizumab)-activated Neoantigen Specific Cellular Therapy ACT adoptive cellular therapy

AEs adverse events

CI confidence intervals

CR complete response

CTL cytotoxic T lymphocytes

DCR disease control rate

DCs dendritic cells

ECOG Eastern Cooperative Oncology Group

ELISPOT enzyme-linked immunospot assay

HLA Human leukocyte antigen

HR hazard ratios

ICIs immune checkpoint inhibitors

MASCT Multiple Antigen Specific Cellular Therapy

MDSC myeloid-derived suppression cells

MHC major histocompatibility complex

NSCLC non-small cell lung cancer

ORR objective response rate

OS overall survival

PBMCs peripheral blood mononuclear cells

PD disease progression

PD-1 Programmed cell death-1

PD-L1 Programmed cell death ligand-1

PFS progression-free survival

PR partial response

RECIST Response Evaluation Criteria in Solid Tumors version 1.1

SD stable disease

SNV single nucleotide variations

Tregs regulatory T cells

WES whole exome sequencing

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval and ethical standards
The study was conducted using a protocol approved by the medical ethics committee of Lianyungang Clinical College of Nanjing Medical University (2017008). All methods and procedures associated with this study were conducted in accordance with the International Conference on Harmonization Good Clinical Practice guidelines, theDeclaration of Helsinki, and Chinese law. These trials were registered with the Clinical Trials Registry (NCT03205930).

Informed consent

Informed consent for protocol therapy, the analysis of blood samples for

Funding

This work was supported by the Jiangsu Province Key Research and Development Plan (Social Development) Project (BE2017684).

Author Contribution

Xiaodong Jiang, Yun Qiao, Kaiyuan Hui and Chenxi Hu participated in the conception and design of this study. Yun Qiao ,Liang Liu,Jingjiao Tang and Xiaodong Jiang contributed to the recruitment of patients and acquisition and analysis and review of the data. Yun Qiao ,Kaiyuan Hui, Chenxi Hu, Mei Wang, Wen Sun conducted the in vitro experiments, analyzed the data, and wrote the manuscript. Xiaodong Jiang supervised the drafting of the manuscript. All authors critically reviewed each draft and approved the version to be published.

Acknowledgments

We thank the patients enrolled in our clinical trials.

Khalil DN, Smith EL, Brentjens RJ, Wolchok JD (2016) The future of cancer treatment: immunomodulation, CARs and combi- nation immunotherapy. Nat Rev Clin Oncol 13(5):273–290. https://doi.org/10.1038/nrclinonc.2016.25
Teng MWL, Ngiow SF, Ribas A, Smyth MJ (2015) Classifying cancers based on T-cell infiltration and PD-L1. Can Res 75(11):2139–2145. https://doi.org/10.1158/0008-5472
Hirokazu Matsushita,Matthew D, Vesely,Daniel C, Koboldt,Charles G Rickert,&Robert D Schreiber(2012)Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.Nature 482(7385):400–404. https://doi.org/10.1038/nature10755
Pan QZ et al (2015) Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer. Oncoimmunology 27(9):e1038017. https://doi.org/10.1080/2162402X.2015.1038017
Haanen JBAG (2017) Converting cold into hot tumors by. combining immunotherapies Cell 170(6):1055–1056. https://doi.org/10.1016/j.cell.2017.08.031
Han Y et al (2017) Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy. J Transl Med 15(1):64. https://doi.org/10.1186/s12967-017-1165-0
Liang LJ, Wen YXHR, Wang Lei,Xia YY,Hu CX,Qiao Y,Geng XW,Chen T Fei JY,Hui KY,Jiang XD(2019)Safety and efficacy of PD-1 blockade‐activated multiple antigen‐specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: a pooled analysis of two prospective trials. Cancer Immunol Immunother 68(9): 1467–1477. https://doi.org/10.1007/s00262-019-02375-z
Rosenthal R, Cadieux EL, Salgado R (2019) Neoantigen-directed immune escape in lung cancer evolution. Nature 567(7749):479–485. https://doi.org/10.1038/s41586-019-1032-7
Yarchoan M et al(2017)Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer 17(9):569. https://doi.org/10.1038/nrc.2017.74
Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L (2023) )Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther 8(1):9. https://doi.org/10.1038/s41392-022-01270-x
Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8(9):1069–1086. https://doi.org/10.1158/2159-8290.CD-18-0367
Ding Z et al (2021) Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduct Target Ther 6(1):26. https://doi.org/10.1038/s41392-020-00448-5
Jin Y, Shao Y, Shi X, Lou G, Zhang Y, Wu X, Tong X, Yu X (2016) Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing. Oncotarget 20(38):61755–61763. https://doi.org/10.18632/oncotarget.11237
Chen F et al(2019)Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. J Clin Invest 129(5):2056–2070.https://doi.org/10.1172/JCI99538
Shukla SA et al (2015) Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol 33(11):1152–1158. https://doi.org/10.1038/nbt.3344
MoH et al (2018) Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR- 1210, an anti-PD-1 antibody in advanced solid tumours: a dose- escalation, phase 1 study. Br J Cancer 119(5):538–545. https://doi.org/10.1038/s41416-018-0100-3
Reuben A et al (2020) Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun 2020, 11(1):603. https://doi.org/10.1038/s41467-019-14273-0
He Y, Guo Y, Chen J, Hu X, Li X, Kong Y, Zhang X, Zhou X, Liu L, Hou J (2018) Multiple Antigen Stimulating Cellular Therapy (MASCT) For Hepatocellular Carcinoma After Curative Treatment: A Retrospective Study. J Cancer 9(8):1385–1393. https://doi.org/10.7150/jca.23725
Jiang N, Qiao G, Wang X, Morse MA, Gwin WR, Zhou L, Song Y, Zhao Y, Chen F, Zhou X, Huang L, Hobeika A, Yi X, Xia X, Guan Y, Song J, Ren J, Lyerly HK (2017) Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. Clin Cancer Res 23(17):5066–5073. https://doi.org/10.1158/1078-0432.CCR-17-0492
Chen (2018) CL Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors. Oncoimmunology 7 (4):e1417721. https://doi.org/10.1080/2162402X.2017.1417721
Apte RS, Chen DS, Ferrara N(2019)VEGF in Signaling and Disease: Beyond Discovery and Development. Cell 176(6):1248–1264. https://doi.org/10.1016/j.cell.2019.01.021

No competing interests reported.

PD-1 Blockade-activated Neoantigen Specific Cellular Therapy For Advanced Relapsed Non Small Cell Lung Cancer

Status:

Version 1

Abstract

Background

Methods

Results

Conclusions

Figures

Introduction

Materials and Methods

Study design and patients

Study treatment

Study endpoints and assessments

Whole Exome Sequencing

Bioinformatics and mutation calling

Human leukocyte antigen (HLA) typing

Neoantigenic peptides(neo-peptides) prediction and prioritization

Generation and assessment of aNASCT

Flow cytometry analysis

IFN-γ Enzyme-Linked Immunospot Assay (ELISPOT)

Statistical Analysis

Results

Patient characteristics and neoantigen identification

Feasibility of aNASCT manufacturing

Safety of aNASCT

Efficiency of aNASCT

Analysis of the circulating T cells

Discussion

Conclusions

Abbreviations

Declarations

Conflict of interest

Informed consent

Funding

Author Contribution

Acknowledgments

References

Additional Declarations

Status:

Version 1